Published in Vaccine Weekly, December 26th, 2001
According to a contingent of investigators at the Iowa City, Iowa university, "Prostatic malignancies in 95% of patients continue to express PSA, making this antigen a good candidate for targeted immunotherapy." Because the cells in the prostrate are significant producers of PSA, they are key targets for directed therapies such as that developed by Bennett D. Elzey and others at University of Iowa.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.